Last reviewed · How we verify

Bupivacaine- physiological solution

SEBASTIAN ROCHE · FDA-approved active Small molecule

Bupivacaine blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and propagation of action potentials.

Bupivacaine is a local anesthetic used for various surgical and diagnostic procedures. It is administered as a physiological solution by SEBASTIAN ROCHE. Despite its effectiveness, it does not have an FDA label, which may limit its use in certain markets. The drug is known for its long-lasting anesthetic properties but comes with a range of potential side effects that need to be carefully managed. Its use is primarily in regional anesthesia, including epidural and spinal blocks.

At a glance

Generic nameBupivacaine- physiological solution
SponsorSEBASTIAN ROCHE
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

By inhibiting sodium influx through ion channels, bupivacaine prevents depolarization of nerve fibers, thereby blocking the initiation and conduction of nerve impulses. This local anesthetic effect is reversible and allows for temporary loss of sensation in a localized area. The physiological solution formulation provides appropriate osmolarity and pH for safe administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: